Regional research priorities for medication safety and pharmacovigilance in gulf cooperation council countries: a modified Delphi consensus study Authors: Ghadah A Assiri, Wael Y Khawagi, Huda Alewairdhi, Fatema A Alqenae, Douha F Bannan, Abdullah A Alshehri, Anas Hamad, Fatma Alraisi, Ghadah H Alshehri Published: 2026 ABSTRACT AbstractAdverse drug reactions (ADRs) and medication errors remain major global threats to patient safety. Although Gulf Cooperation Council (GCC) countries have advanced medication safety and pharmacovigilance programs, research priorities remain fragmented and lack expert consensus. To establish consensus on medication safety and pharmacovigilance research priorities across GCC countries using a modified Delphi approach. A two-round, web-based modified Delphi study was conducted between November 2024 and September 2025. Experts from Saudi Arabia, Qatar, Oman, Kuwait, Bahrain, and the United Arab Emirates were recruited based on professional experience. Participants rated research priorities using a 9-point Likert scale. Consensus was defined as ≥ 80% of participants rating an item 7–9 and < 15% rating it 1–3. Quantitative data were analysed descriptively, and qualitative feedback informed item refinement. A total of 38 experts completed both Delphi rounds (response rate: 79.2%). In Round 1, 30 out of 47 priorities (63.8%) achieved consensus. In Round 2, five additional items reached consensus, resulting in a final set of 35 priorities (74.5%). The highest agreement was observed in the Healthcare Professionals domain (100%), followed by Medicines (77.8%), Patients and the Public (72.7%), and Systems and Practices (69.6%). Key priorities included addressing inappropriate polypharmacy, improving human factors and system design, enhancing patient safety at home, and strengthening reporting and surveillance systems. This Delphi study identified regional research priorities to guide medication safety and pharmacovigilance efforts across the GCC. The findings offer a structured research agenda to inform policy, funding decisions, and institutional strategies, while supporting global patient safety goals.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s44446-026-00112-z.Keywords: Pharmacovigilance, Medication safety, Delphi study, GCC, Research priorities, Patient safety Introduction Ensuring the safe and effective use of medicines remains a cornerstone of public health and clinical care (Panagioti et al. 2019). Despite significant advances in therapeutics, adverse drug reactions (ADRs) and medication errors continue to represent major causes of morbidity, mortality, and healthcare expenditure worldwide (Bates and Singh 2018; Mejía et al. 2020; Elliott et al. 2021). Both medication safety and pharmacovigilance play pivotal roles in minimizing these risks (Beninger 2018; Bates et al. 1995). Pharmacovigilance focuses on the detection, assessment, and prevention of adverse effects associated with medicines, whereas medication safety encompasses a broader, system-based approach to preventing errors across all stages of the medication-use process. Together, these disciplines form complementary pillars of patient safety (Bates and Singh 2018; Elseviers et al. 2024). Recognizing the global burden of unsafe medication practices, the World Health Organization (WHO) launched the Global Patient Safety Challenge: Medication Without Harm in 2017 (Donaldson et al. 2017). In response to this challenge, increasing attention has been directed toward defining research priorities that can guide policy and practice in these interrelated fields. In a landmark international consensus exercise, Sheikh et al. (2019a, b) identified key global research priorities for medication safety, emphasizing the need to strengthen surveillance systems, improve reporting culture, and promote safer medication-use environments through multidisciplinary collaboration and evidence-based interventions (Sheikh et al. 2019a). However, translating these global priorities into regional or national research agendas remains a challenge, particularly in regions with evolving healthcare systems such as the Gulf Cooperation Council (GCC) countries. In recent years, countries within the GCC, including Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain, have made substantial progress in developing national pharmacovigilance centres, reporting systems, and medication safety programs (Alsaidan et al. 2018; Assiri et al. 2018; Qato 2018). National authorities such as the Saudi Food and Drug Authority (SFDA) and health institutions have implemented initiatives to improve ADR reporting, error prevention, and awareness among healthcare professionals (Alghamdi 2025). However, there remains a need for strategic alignment and prioritization of research efforts to strengthen both pharmacovigilance and medication safety systems across the region. Research priorities in these domains are often determined by fragmented initiatives or institutional interests rather than by a shared regional framework grounded in expert consensus (Sheikh et al. 2019a). Identifying and prioritizing research areas through a structured, evidence-informed approach is essential to guide policymakers, funding agencies, and academic institutions toward impactful investigations that address regional challenges and align with global medication safety goals (Nyanchoka et al. 2019; Wong et al. 2022; Bates et al. 2009). Therefore, this study aimed to identify and establish consensus on the most important pharmacovigilance and medication safety research priorities in the GCC countries using a multi-round Delphi process involving experts from academia, healthcare practice, and regulatory sectors. Methods Study design A two-round modified Delphi technique was employed to achieve expert consensus on research priorities related to pharmacovigilance and medication safety in the GCC countries. This structured, iterative approach was selected for its effectiveness in synthesizing expert opinions where empirical evidence may be limited (De Villiers et al. 2005). Data collection was conducted between November 2024 and September 2025. This study is reported in accordance with the Conducting and REporting of DElphi Studies (CREDES) guidance to ensure transparency and methodological rigor (Jünger et al. 2017). Expert panel selection and recruitment Experts were purposefully selected from all six GCC countries, Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain, to ensure comprehensive regional representation. We approached at least three healthcare professional experts from each country who specialized in pharmacovigilance or medication safety. Eligible participants were required to have published at least two articles in reputable peer-reviewed journals in these fields and/or to be serving as medication safety officers within healthcare institutions. A multi-source recruitment strategy was employed to identify and engage potential participants. First, we utilized a professional network that included members of the Medication Safety Officer group and relevant contacts on social media platforms, which provided an effective channel for reaching professionals actively involved in pharmacovigilance and medication safety initiatives. Second, we collaborated with national and regional institutions, such as the Saudi Health Council and similar regulatory and professional bodies across GCC countries, to identify recognized experts and nominees actively engaged in national medication safety and pharmacovigilance programs. Third, we conducted a targeted search of scholarly publications to identify authors of relevant pharmacovigilance and medication safety studies published in reputable medical and pharmacy journals. This approach ensured that the panel included experts with proven academic and professional experience, as well as representation from regulatory, clinical, and academic sectors. Eligibility criteria were confirmed prior to participant recruitment. Professional credentials for published outputs were confirmed through database searching (such as PubMed, and Web of Science) along with participants' professional affiliation or contact. Through such confirmations, it was possible to include participants who had academic and professional expertise from different areas such as regulation, practice, and academia. Invitations were sent via personalized email describing the study objectives, the Delphi process, expected time commitment, and the voluntary nature of participation. To ensure balanced perspectives, the recruitment strategy aimed to include experts from academia, clinical practice, regulatory agencies, and healthcare organizations. Electronic informed consent was obtained from all participants prior to the start of the first Delphi round. Identifying preliminary list of research priorities The initial list of research priorities was developed through a structured and iterative process that combined evidence from the literature with contextual adaptation to the GCC setting. A comprehensive review of existing literature was conducted, guided by the international prioritization exercise by Sheikh et al. (2019a, b), which provided a foundational framework for identifying and categorizing research topics in medication safety (Sheikh et al. 2019a). To ensure regional relevance, the research team supplemented this framework by reviewing additional studies and reports focusing on pharmacovigilance and medication safety within the Middle East and GCC countries. These sources were used to identify context-specific issues such as variations in reporting systems, healthcare infrastructure, regulatory environments, and patient engagement practices across the region. Based on this synthesis, an initial pool of research priorities was generated and mapped into four main domains: Patients and the Public, Medicines, Healthcare Professionals, and Systems and Practices. The first domain addressed aspects related to patient engagement, education, awareness, and communication about medication safety. The second domain focused on medicines themselves, including issues related to formulation, labelling, packaging, storage, and post-marketing safety monitoring. The third domain covered healthcare professionals’ knowledge, attitudes, and practices, as well as training and reporting behaviours. The fourth domain examined system-level factors such as safety culture, reporting mechanisms, data infrastructure, policy development, and regulatory frameworks. The preliminary list was further refined through iterative discussions within the research team, which included experts with experience in pharmacovigilance, clinical practice, and healthcare systems in the region. During this stage, items were reviewed for clarity, redundancy, and contextual applicability, and modifications were made to ensure that the priorities were relevant and meaningful within GCC healthcare settings. The finalized list was incorporated into the first-round Delphi questionnaire. In addition to rating the proposed priorities, participants were invited to suggest new research questions or propose modifications to existing items to further enhance contextual relevance. The detailed list of items and corresponding domains is provided in Appendix 1 of the Electronic Supplementary Material (ESM). Delphi procedure The Delphi process consisted of two rounds of web-based questionnaires administered using Research Electronic Data Capture (REDCap). For each round, a secure link to the relevant questionnaire was sent via email to all panel members, accompanied by clear instructions for completion and the purpose of each round. Participants were asked to rate the importance of each proposed research priority using a 9-point Likert scale, where 1 indicated least important and 9 indicated most important. If participants felt that an item was beyond their area of expertise, they were instructed to select “don’t know.” Each round remained open for two weeks, and a reminder email was sent one week after the initial invitation to encourage completion. In the first round, participants reviewed and rated all proposed research priorities and were also invited to suggest additional items or recommend modifications to existing ones. The second round included all items that did not achieve consensus in the first round, allowing participants to reconsider their ratings in light of group feedback. Consensus was defined a priori as occurring when at least 80% of participants rated an item as 7–9 (important or very important) and fewer than 15% rated it as 1–3 (least important). Items meeting these criteria were retained as priority areas, while those not reaching consensus were re-rated in the second round. After each round, results were summarized and shared with participants in an anonymized format, providing an opportunity to reflect on the group’s collective responses before submitting their final ratings. Statistical analysis Quantitative data were analysed using descriptive statistics (median, interquartile range, and percentage agreement) to assess the level of consensus for each item. Descriptive statistics were selected as they are recommended for Delphi studies to summarize expert agreement and central tendency without assuming normal distribution of responses. Qualitative comments were thematically analysed and integrated into subsequent Delphi rounds when appropriate. The results from both rounds were organized and summarized in tabular form to display the number of items rated, those achieving consensus, and those carried forward for re-evaluation. Further analyses were performed by grouping the items according to the four predefined research domains to allow comparison of consensus distribution across thematic areas. Stability of responses between rounds was assessed by comparing median scores and percentage agreement across rounds, with minimal variation indicating consistency in expert opinions. Data were managed and analysed using Microsoft Excel®. Results Characteristics of the expert panel A total of 48 experts were invited to participate, of whom 38 agreed to participate (response rate: 79.2%) and completed both Round 1 and Round 2, without any attrition across rounds. Nearly half were from Saudi Arabia (47.4%), followed by Qatar (28.9%), Oman (15.8%), and Kuwait (7.9%). While all participants had a pharmacy background, they represented a broad range of practice domains, including academia (44.7%), clinical and hospital practice (34.2%), medication safety officers (18.4%), and regulatory affairs (2.6%). In terms of professional experience, 36.8% had ≤ 10 years, 18.4% had 11–15 years, 34.2% had 16–20 years, and 10.5% had ≥ 21 years of experience. No participants were recruited from Bahrain or the United Arab Emirates during Round 1, despite outreach efforts. Details of expert characteristics are presented in Table 1. The Delphi study process, including item progression across rounds, is illustrated in Fig. 1. Table 1Characteristics of Delphi expert panel (n = 38)Characteristicn (%)Country Saudi Arabia18 (47.4%) Qatar11 (28.9%) Oman6 (15.8%) Kuwait3 (7.9%)Pharmacy Profession Academia17 (44.7%) Practice (Clinical/Hospital/Community)13 (34.2%) Medication Safety Officers7 (18.4%) Regulatory Affairs1 (2.6%)Years of Experience ≤ 10 years14 (36.8%) 11–15 years7 (18.4%) 16–20 years13 (34.2%) ≥ 21 years4 (10.5%) Characteristics of Delphi expert panel (n = 38) Flowchart of the Delphi process First round In the first Delphi round, experts evaluated 47 proposed research priorities divided according to the four domains. Using the predefined threshold for consensus (≥ 80% of participants rating an item 7–9 and < 15% rating it 1–3), 30 priorities (63.8%) achieved consensus and were included in the final list. The remaining 17 items (36.2%) did not achieve consensus and were carried forward to Round 2 for re-evaluation. The median scores for the items in Round 1 ranged between 7 and 9, with interquartile ranges (IQR) generally narrow, indicating strong agreement among participants. On average, 82% of ratings fell within the 7–9 range, while only 2.4% fell in the 1–3 range, suggesting that very few items were considered unimportant by the expert panel. The priorities that reached consensus covered a wide scope of domains, including the prevalence and consequences of inappropriate polypharmacy, the role of community pharmacists in promoting safe medication use, human factors contributing to errors, and the identification of high-risk patient groups. By contrast, the items not achieving consensus tended to represent more specific or emerging areas, such as methodological capacity building and the development of novel measurement indicators, which required further deliberation in Round 2. The three items that achieved the strongest consensus in Round 1 reflected core themes in pharmacovigilance and medication safety. The first was “To assess the prevalence and consequences of inappropriate polypharmacy and develop strategies to minimize harm and improve health outcomes,” which received a median score of 8 (IQR = 2), with 97.3% of participants rating it 7–9 and none rating it 1–3. The second highest-ranked priority was “To identify and prioritize human factors, ergonomics, and error-proof design in healthcare settings that contribute to safe medication practices,” which also scored a median of 8 (IQR = 2), with 97.2% agreement in the 7–9 range and 0% in the 1–3 range. The third was “To identify the most frequent medication errors made by patients at home and evaluate strategies to prevent these errors,” which achieved a median of 8 (IQR = 1), with 92.1% of ratings in the 7–9 range and 0% in the 1–3 range. Although participants were asked to suggest additional research priorities in Round 1. All additional items suggested were carefully evaluated by the research team and were found to overlap with existing items. Therefore, no additional items were introduced in Round 2. Second round In the second round, the 17 items that had not reached consensus in Round 1 were re-evaluated by the expert panel. Following re-rating, 5 additional items achieved consensus (29.4%), while 12 items remained below the threshold and were excluded from the final set of priorities. Consensus results are summarized in Table 2. Table 2Summary of consensus outcomes across Delphi roundsDelphi roundTotal items ratedAchieved consensusDid not reach consensus% Achieved consensusRound 147301763.8%Round 21751229.4%Total47351274.5% Summary of consensus outcomes across Delphi rounds Overall, the two-round Delphi process resulted in a final set of 35 (74.5%) research priorities that reflect expert consensus on pharmacovigilance and medication safety research needs across the GCC region (Table 3). Final consensus priorities (n = 35) were distributed across four domains, with the highest agreement observed in the Healthcare Professionals domain (100% consensus), followed by Medicines (77.8%), Patients and the Public (72.7%) and Systems and Practices (69.6%). Domain-level breakdown is shown in Table 4 and Fig. 2. Table 3Final consensus medication safety research priorities identified by the Delphi expert panel (n = 35)DomainResearch priorityHealthcare ProfessionalsTo identify and prioritize human factors, ergonomics, and error proof design in healthcare settings that contribute to safe medication practicesTo raise awareness among Ministries of Health and healthcare leaders about the importance of medication safety in primary careTo assess the effectiveness of healthcare professionals and trained workforce configurations in preventing and reducing medication errorsTo identify and assess effective and sustainable educational tools (e.g., digital tools, workshops) for healthcare professionals to provide information about the safe use of medications to patients and caregiversMedicinesTo assess the prevalence and consequences of inappropriate polypharmacy and develop strategies to minimize harm and improve health outcomesTo assess the prevalence and magnitude of severe drug interactions due to polypharmacy in elderly peopleTo investigate the prevalence and impact of medication errors related to extemporaneous compounding for paediatric patients and strategies to mitigate these risksTo assess factors influencing medication adherence from both patient and healthcare professional perspectivesTo determine the extent of harm caused by substandard, spurious, falsified, and counterfeit medicines (SSFFCs) and develop strategies to reduce their prevalence in GCC countriesTo evaluate the role of medication dispensing technology (e.g., automated dispensing cabinets) in reducing medication errorsTo identify strategies to prevent inappropriate self-medication with antibioticsPatients and the PublicTo identify the most frequent medication errors made by patients at home and evaluate strategies to prevent these errorsTo identify patient groups and disease types that correlate with a higher risk of medication related errors and determine the benefit of routine medication reviews and reconciliation for these groups related errors and determine the benefit of routine medication reviews and reconciliation for these groupsTo explore patient perspectives on their role in medication management during transitions of care and identify strategies, barriers, and facilitators to improve patient engagement in medication managementTo implement and evaluate interventions and WHO recommendations to ensure the correct dosage and safety of medications for paediatric patientsTo assess the impact of current prescription and medication use patterns during pregnancy on adverse birth outcomes in GCC countriesTo identify the challenges and resources required for effective patient and caregiver involvement in improving medication safety and strategies to enhance engagement among patients and their familiesTo identify factors influencing patient decision making about polypharmacy and develop decision aids to help patients participate in discussions around managing multiple medicationsTo study the effectiveness of patient user strategies (such as e-health, digital health tools, and patient information services) in promoting safe medication use and improving medication adherenceSystems and PracticesTo evaluate the role of community pharmacists in safe medication practices, including annual medication reviews, and assess the impact of providing patient therapy information to reduce medication errorsTo examine the role of IT and AI, including decision support tools and electronic prescribing systems, in enhancing medication safety, optimizing decision support alerts, and assisting clinicians in safe prescription practicesTo assess the prevalence and burden of medication errors, adverse drug events, and serious medication related harm in primary care in GCC countries and their geographical variationTo conduct a study investigating the types of medication related harm that occur in transitions between hospitals and primary care settingsTo examine ambulatory practice prescribing and which types of medications, or combinations of medications, carry a high risk of safety problems in patientsTo identify the enablers and barriers in identifying serious medication related harm in GCC countriesTo evaluate the effectiveness of interventions aimed at improving medication safety during transitions of care, including medication reconciliation, effective communication strategies, and technology assisted systemsTo assess the cost effectiveness of different evidence-based interventions to reduce, eliminate, or ameliorate medication related patient harmTo conduct studies across primary care facilities to assess medication safety and explore strategies for improvementTo assess the prevalence and burden of medication errors, adverse drug events, and serious medication related harm in hospitals in GCC countries and their geographical variationTo examine barriers and enhance medication error reporting and learning systems, focusing on successful interventions in GCC countriesTo investigate the perceived causes of unsafe medication practices and evaluate differences in contributing factors across healthcare levels (primary, secondary, tertiary) and systemsTo design technology assisted medication administration systems to reduce medication errors, e.g., two tier level identificationTo study national policies and strategies for medication safety and their impact on reducing medication errors and improving patient outcomes across GCC countriesTo identify the prevalence and causes of medication administration errors and adverse drug eventsTo identify the challenges and opportunities for healthcare professionals and the healthcare system to improve medication safety in transitions of careThis table presents the final set of 35 research priorities that achieved expert consensus across two Delphi rounds. Consensus was defined a priori as ≥ 80% of participants rating an item 7–9 and < 15% rating it 1–3 Final consensus medication safety research priorities identified by the Delphi expert panel (n = 35) This table presents the final set of 35 research priorities that achieved expert consensus across two Delphi rounds. Consensus was defined a priori as ≥ 80% of participants rating an item 7–9 and < 15% rating it 1–3 Table 4Consensus outcomes by research domainDomainTotal itemsAchieved consensus% AchievedNot achieved% Not achievedPatients and the Public11872.7%327.3%Medicines9777.8%222.2%Healthcare Professionals44100%00%Systems and Practices231669.6%730.4%Total473574.5%1225.5% Consensus outcomes by research domain Consensus outcomes by research domain Median scores in Round 2 ranged between 7 and 9, with interquartile ranges that were generally narrower compared to Round 1, reflecting increased convergence of expert opinion. The percentage of participants rating items in the 7–9 range also increased for the items that ultimately reached consensus, supporting the benefit of iterative re-evaluation in the Delphi process. Full scoring results are shown in Appendix 2, of the ESM. Discussion This Delphi study represents the first regional effort to systematically identify and prioritize pharmacovigilance and medication safety research priorities across the GCC countries. The final set of priorities reflects shared perspectives across academia, clinical practice, and regulatory sectors, and highlights research areas that are both globally aligned and regionally distinct. The findings align broadly with international patient safety agendas, including the WHO Global Patient Safety Challenge: Medication Without Harm, and prior global priority-setting initiatives in patient safety (Sheikh et al. 2019a; Donaldson et al. 2017). Similar to these global initiatives, experts in this study placed strong emphasis on polypharmacy, human factors, surveillance systems, and improving reporting culture. However, the priorities identified here extend the international agenda by contextualizing these needs to the unique healthcare, regulatory, and sociocultural structures of GCC countries (Alruthia et al. 2025; Khoja et al. 2017; Sheikh et al. 2019b). Unlike the global prioritization exercise, this GCC-based study emphasized region-specific needs, including variability in medication safety infrastructure, limited integration of pharmacovigilance data systems, and the need for methodological capacity building in pharmacoepidemiologic research. These findings suggest that while global frameworks provide valuable direction, contextual adaptation is essential for addressing local healthcare system structures, workforce capacities, and regulatory environments in the GCC countries (Breneol et al. 2022). The highest-ranked priorities, such as minimizing inappropriate polypharmacy, integrating human-cantered design into care processes, and identifying frequent errors in community settings, highlight issues arising from expanding chronic disease burdens and increasing therapeutic complexity (Koné Pefoyo et al. 2015; Yach et al. 2004). Several priorities called for improved evidence on safety during care transitions between primary, secondary, and tertiary settings, reflecting fragmentation in continuity of care and limited integration of medication records across institutions. These findings align with emerging regional literature documenting preventable harm related to duplication, omissions, reconciliation failure, and provider communication challenges (Alsaidan et al. 2018; Alshehri et al. 2024). The unanimous consensus in the Healthcare Professionals domain suggests broad agreement on the central role of clinicians, especially pharmacists, in improving medication safety (Mansur 2016; Maxwell and Webb 2019). Priorities emphasizing education, competency development, and professional training indicate recognition that safety culture and reporting behaviour are influenced by workforce preparedness. Although GCC countries have invested in pharmacist-led medication safety roles within hospitals, variation in role structure, authority, and expectations may limit impact (Alghamdi 2025). Strengthening standardized training programs, multidisciplinary collaboration, and regulatory oversight may enhance the capacity of healthcare professionals to lead safety improvements across settings (Bates and Singh 2018; Maxwell and Webb 2019). However, it is important to note that the expert panel consisted exclusively of pharmacists. While pharmacists play a central role in medication safety, the absence of physicians and nurses, who are directly involved in prescribing and medication administration, may have influenced the prioritization of research areas, particularly those related to prescribing practices and frontline clinical processes. A notable theme in this study was the prominence of technology-related priorities, including electronic prescribing, clinical decision support, automated dispensing, and digital tools to enhance adherence and patient education. While these innovations are increasingly integrated into GCC health systems, their implementation remains heterogeneous and often lacks rigorous evaluation (Weber et al. 2017; Pawar et al. 2025; Al Salmi et al. 2025; Shafei and Taher 2024). Priorities identified here highlight the need for research assessing cost-effectiveness, usability, system integration, and safety outcomes, rather than assuming inherent benefit. This aligns with global trends toward digitized medication systems but requires methodological approaches that account for variability in infrastructure, vendor systems, governance structures, and digital maturity across GCC countries (Gates et al. 2021). These findings hold significant implications for clinical practice. The demonstrated prevalence and consequences of inappropriate polypharmacy highlight the urgency of implementing structured medication reviews and deprescribing protocols, particularly for high-risk populations with multimorbidity. In addition, a systematic understanding of medication burden enables practitioners to identify patterns of overprescribing, drug–drug interactions, and adverse drug events that compromise patient outcomes. Integrating human factors and ergonomic principles into healthcare design could enhance usability, reduce the cognitive burden on both patients and providers, and minimize preventable medication errors. Furthermore, recognising common errors occurring in community and home settings supports the development of targeted educational interventions and clearer communication strategies. The identification of vulnerable patient groups reinforces the value of routine medication reconciliation as a standard of care to ensure continuity and accuracy across transitions. Importantly, the expanded role of community pharmacists in delivering medication reviews and patient counselling represents a practical strategy that could improve adherence, optimise therapeutic outcomes, and strengthen overall medication safety within healthcare organizations. By providing a structured agenda, this study can guide investment toward high-impact research areas, reduce duplication of efforts across institutions, and support coordinated implementation of region-wide safety strategies (Sheikh et al. 2019b; Bates et al. 2009). The priorities can also inform national medication safety roadmaps, accreditation standards, and training frameworks, and may help establish shared metrics and indicators for monitoring safety initiatives across GCC states. Establishing a regional network for medication safety and pharmacovigilance research would facilitate data sharing, build research capacity, and promote harmonization of safety reporting systems. Additionally, several underexplored areas—such as methodological capacity building, policy evaluation, and the development of validated safety indicators—require focused attention to ensure that future initiatives not only identify safety challenges but also generate measurable improvements in medication-use outcomes across the region (Avery et al. 2011; Khawagi et al. 2021, 2025). This study offers several strengths, including representation from multiple countries and diverse professional backgrounds, and the use of a Delphi methodology that enables iterative refinement and minimizes dominance bias (De Villiers et al. 2005). The structured recruitment strategy, which drew from professional networks, regulatory bodies, and published authors, ensured inclusion of experts with both academic and applied experience in medication safety. However, limitations must be considered when interpreting the results. A limitation of this study is the lack of representation from Bahrain and the UAE despite outreach efforts, as well as the overrepresentation of certain countries, which may affect the generalizability of the findings across the GCC. The panel consisted exclusively of pharmacists, resulting in underrepresentation of perspectives from physicians, nurses, patient representatives, and governmental leadership, all of whom play critical roles in medication safety policy and implementation. This may have shaped the prioritization toward pharmacy-centric perspectives, potentially overlooking system-level or patient-cantered considerations from other disciplines. The use of purposive sampling and voluntary participation may have introduced selection bias, as individuals with greater interest or experience in medication safety and pharmacovigilance may have been more likely to participate. Future research may also expand the panel to include a broader range of stakeholders and apply prioritization frameworks that incorporate feasibility, burden of disease, and cost–benefit considerations. While the Delphi method is well suited for consensus formation, it relies on perceptions rather than empirical feasibility; therefore, the priorities identified here should be further evaluated for resource requirements such as healthcare infrastructure and digital maturity, implementation readiness and challenges, as well as expected impact. Given the variability in digital maturity and healthcare capacity across GCC countries, the feasibility and scalability of implementing these priorities may differ substantially between settings. Accordingly, this represents an important area for future research. Conclusion This study provides the first expert-driven consensus research agenda for pharmacovigilance and medication safety across GCC countries. The findings reflect both alignment with global medication safety priorities and the distinct contextual needs of regional healthcare systems. These priorities provide a strategic framework for guiding future research, fostering collaboration, and supporting policy efforts aimed at achieving safer medication practices and reducing preventable harm across the Gulf region. Future efforts should focus on operationalizing these priorities through multicounty research programs and involving additional stakeholders to ensure sustained impact in reducing medication-related harm across the GCC. Future research should also include feasibility and implementation studies to assess how these priorities can be operationalized across countries with varying levels of digital maturity, healthcare infrastructure, and system readiness. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 48.1 KB) Supplementary file2 (DOCX 42.4 KB) Author contribution Conceptualization: Ghadah A. Assiri, Wael Y. Khawagi, Fatema A. Alqenae, Huda Alewairdhi, Douha F. Bannan, Abdullah A. Alshehri, Anas Hamad, Fatma Alraisi, Ghadah H. Alshehri. Data curation: Ghadah A. Assiri, Wael Y. Khawagi, Fatema A. Alqenae, Huda Alewairdhi, Douha F. Bannan, Abdullah A. Alshehri, Anas Hamad, Fatma Alraisi, Ghadah H. Alshehri. Formal analysis: Ghadah A. Assiri, Wael Y. Khawagi. Funding acquisition: Ghadah H. Alshehri. Investigation: Ghadah A. Assiri, Wael Y. Khawagi, Fatema A. Alqenae, Huda Alewairdhi, Douha F. Bannan, Ghadah H. Alshehri. Methodology: Ghadah A. Assiri, Wael Y. Khawagi, Fatema A. Alqenae, Huda Alewairdhi, Douha F. Bannan, Ghadah H. Alshehri.Project administration: Ghadah A. Assiri, Wael Y. Khawagi. Software: Ghadah A. Assiri, Wael Y. Khawagi, Ghadah H. Alshehri. Validation: Ghadah A. Assiri, Wael Y. Khawagi. Writing – original draft: Ghadah A. Assiri, Wael Y. Khawagi, Huda Alewairdhi, Douha F. Bannan. Writing – review & editing: All authors. Funding This research was funded by the Princess Nourah bint Abdulrahman University Researchers Support Initiative (PNURSP2026R352), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Data availability Data is provided within the manuscript or supplementary information file. Declarations Competing interests The authors have no relevant competing interests to declare Ethical statement Ethical approval for this study was obtained from the Institutional Review Board (IRB) at King Saud University (KSU) under research project number E-22–7278. To ensure participant confidentiality and data protection, all raw data collected during the Delphi rounds were stored securely and were not made publicly available. The identity of each participant remained anonymous to other panel members throughout all stages of the study. Prior to participation, all experts were required to provide informed consent, which was obtained electronically through a consent statement embedded on the first page of the questionnaire. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Ghadah A. Assiri and Wael Y. Khawagi contributed equally to this work. References Associated Data Supplementary Materials Supplementary file1 (DOCX 48.1 KB) Supplementary file2 (DOCX 42.4 KB) Data Availability Statement Data is provided within the manuscript or supplementary information file.